![Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab - ScienceDirect Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497122006905-grabsf1.jpg)
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab - ScienceDirect
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i> analyses from the phase III MURANO study | Haematologica
![Matthew Cheung on X: "MURANO trial in R/R CLL(late breaking #ASH17): venetoclax-R vs BR associated with improved PFS (2-yr 85% vs 36%; HR 0.17, p<0.0001) and OS (92% vs 87%; HR 0.48) Matthew Cheung on X: "MURANO trial in R/R CLL(late breaking #ASH17): venetoclax-R vs BR associated with improved PFS (2-yr 85% vs 36%; HR 0.17, p<0.0001) and OS (92% vs 87%; HR 0.48)](https://pbs.twimg.com/media/DQ2QjbwXcAEkqfa.jpg)
Matthew Cheung on X: "MURANO trial in R/R CLL(late breaking #ASH17): venetoclax-R vs BR associated with improved PFS (2-yr 85% vs 36%; HR 0.17, p<0.0001) and OS (92% vs 87%; HR 0.48)
Carmen Murano - Higher Scientific Officer | Translational Immunotherapy Team | Radiotherapy and Imaging Division - The Institute of Cancer Research | LinkedIn
![Jeff Szer on X: "John Seymour from @Haem_pmcc_rmh presenting MURANO trial of time-limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). #ASH18 https://t.co/aCOdDI4yC2" / X Jeff Szer on X: "John Seymour from @Haem_pmcc_rmh presenting MURANO trial of time-limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). #ASH18 https://t.co/aCOdDI4yC2" / X](https://pbs.twimg.com/media/DtXbXyeU0AEoVQC.jpg)
Jeff Szer on X: "John Seymour from @Haem_pmcc_rmh presenting MURANO trial of time-limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). #ASH18 https://t.co/aCOdDI4yC2" / X
![Lymphoma Hub on X: "CONGRESS | #ASH20 | Arnon Kater, @amsterdamumc, reports long term results in phase III MURANO study of fixed-duration venetoclax-rituximab with standard bendamustine-rituximab in R/R CLL. 5-yr data showed Lymphoma Hub on X: "CONGRESS | #ASH20 | Arnon Kater, @amsterdamumc, reports long term results in phase III MURANO study of fixed-duration venetoclax-rituximab with standard bendamustine-rituximab in R/R CLL. 5-yr data showed](https://pbs.twimg.com/media/EofjiYQXUAEykJZ.jpg)
Lymphoma Hub on X: "CONGRESS | #ASH20 | Arnon Kater, @amsterdamumc, reports long term results in phase III MURANO study of fixed-duration venetoclax-rituximab with standard bendamustine-rituximab in R/R CLL. 5-yr data showed
![Lymphoma Hub on X: "#EHA2023 | Arnon Kater @amsterdamumc shares the final 7-year follow up data from the MURANO trial of VenR in R/RCLL. OS 69.6% and 51% in VenR and BR Lymphoma Hub on X: "#EHA2023 | Arnon Kater @amsterdamumc shares the final 7-year follow up data from the MURANO trial of VenR in R/RCLL. OS 69.6% and 51% in VenR and BR](https://pbs.twimg.com/media/FyVV2j9WAAAoiQR.jpg:large)
Lymphoma Hub on X: "#EHA2023 | Arnon Kater @amsterdamumc shares the final 7-year follow up data from the MURANO trial of VenR in R/RCLL. OS 69.6% and 51% in VenR and BR
![Korea Ins Style Striped Mushroom Table Lamp Murano Style Striped Glass Lamp, Study, Bedside Living Room Lamp for Bedroom Korea Ins Style Striped Mushroom Table Lamp Murano Style Striped Glass Lamp, Study, Bedside Living Room Lamp for Bedroom](https://ae01.alicdn.com/kf/Se40b0ec4f8624c989b3d6c607793c290U/Korea-Ins-Style-Striped-Mushroom-Table-Lamp-Murano-Style-Striped-Glass-Lamp-Study-Bedside-Living-Room.jpg)
Korea Ins Style Striped Mushroom Table Lamp Murano Style Striped Glass Lamp, Study, Bedside Living Room Lamp for Bedroom
![JWCN Glass Mushroom Table Lamp, LED Bedside Murano Style Striped Night Lamps For Home Study Room Bedroom, Kids Room Decorative,Uptodate JWCN Glass Mushroom Table Lamp, LED Bedside Murano Style Striped Night Lamps For Home Study Room Bedroom, Kids Room Decorative,Uptodate](https://m.media-amazon.com/images/I/51cpQnnOwaL.jpg)
JWCN Glass Mushroom Table Lamp, LED Bedside Murano Style Striped Night Lamps For Home Study Room Bedroom, Kids Room Decorative,Uptodate
![PDF) Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study PDF) Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study](https://i1.rgstatic.net/publication/329460708_Fixed_Duration_of_Venetoclax-Rituximab_in_RelapsedRefractory_Chronic_Lymphocytic_Leukemia_Eradicates_Minimal_Residual_Disease_and_Prolongs_Survival_Post-Treatment_Follow-Up_of_the_MURANO_Phase_III_Stu/links/5d650f8c92851c619d797fd3/largepreview.png)
PDF) Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
![Murano 12' threatened with eviction and £1,200 fine after suffering trauma from external parties - The Glasgow Guardian Murano 12' threatened with eviction and £1,200 fine after suffering trauma from external parties - The Glasgow Guardian](https://i0.wp.com/glasgowguardian.co.uk/wp-content/uploads/sites/2/2016/03/Murano-Street4.jpg?fit=977%2C550&ssl=1)
Murano 12' threatened with eviction and £1,200 fine after suffering trauma from external parties - The Glasgow Guardian
![Lymphoma Hub on X: "CONGRESS | #ASH20 | Arnon Kater, @amsterdamumc, reports long term results in phase III MURANO study of fixed-duration venetoclax-rituximab with standard bendamustine-rituximab in R/R CLL. 5-yr data showed Lymphoma Hub on X: "CONGRESS | #ASH20 | Arnon Kater, @amsterdamumc, reports long term results in phase III MURANO study of fixed-duration venetoclax-rituximab with standard bendamustine-rituximab in R/R CLL. 5-yr data showed](https://pbs.twimg.com/media/EofjiWXXMAMWFvX.jpg)
Lymphoma Hub on X: "CONGRESS | #ASH20 | Arnon Kater, @amsterdamumc, reports long term results in phase III MURANO study of fixed-duration venetoclax-rituximab with standard bendamustine-rituximab in R/R CLL. 5-yr data showed
![University of Glasgow - Undergraduate study - Undergraduate accommodation - Residence profiles - Murano Street Student Village University of Glasgow - Undergraduate study - Undergraduate accommodation - Residence profiles - Murano Street Student Village](https://i.ytimg.com/vi/Be34VZPL26g/mqdefault.jpg)
University of Glasgow - Undergraduate study - Undergraduate accommodation - Residence profiles - Murano Street Student Village
![Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - ScienceDirect Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497118582732-gr1.jpg)